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Background: Upon virus infection, cells secrete a diverse group of antiviral molecules that signal proximal cells to
enter into an antiviral state, slowing or preventing viral spread. These paracrine signaling molecules can work
synergistically, so measurement of any one antiviral molecule does not reflect the total antiviral activity of the
system.
Results: We have developed an antiviral assay based on replication inhibition of an engineered fluorescent
vesicular stomatitis virus reporter strain on A549 human lung epithelial cells. Our assay provides a quantitative
functional readout of human type I, II, and III interferon activities, and it provides better sensitivity, intra-, and inter-
assay reproducibility than the traditional crystal violet based assay. Further, it eliminates cell fixation, rinsing, and
staining steps, and is inexpensive to implement.
Conclusions: A dsRed2-strain of vesicular stomatitis virus that is sensitive to type I, II, and III interferons was used to
develop a convenient and sensitive assay for interferon antiviral activity. We demonstrate use of the assay to
quantify the kinetics of paracrine antiviral signaling from human prostate cancer (PC3) cells in response to viral
infection. The assay is applicable to high-throughput screening for anti-viral compounds as well as basic studies of
cellular antiviral signaling.
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Mammalian cells respond to virus infection by synthesiz-
ing and secreting a host of antiviral molecules that are not
only involved in recruitment of immune effector cells and
activation of adaptive immunity, but also control localized
spread of virus infection via mechanisms of “cell-intrinsic”
innate immunity. These secreted antiviral molecules, first
described collectively in 1957 as “interferon”, establish an
anti-viral state within the infected cell, and signal other
cells to react in an antiviral manner [1,2].
Antivirals secreted by non-immune cells comprise a
diverse mixture of molecules which exert a combined
paracrine effect on proximal cells. These include, for ex-
ample, the classic type I interferons (IFNα/β, etc.) [3,4],
type II interferon (IFNγ), and type III interferons (IFNλs)* Correspondence: yin@engr.wisc.edu
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reproduction in any medium, provided the or[5-9]. While type I interferons are known to play import-
ant roles in host antiviral responses, for many viruses
such as human rhinovirus and influenza infections of
bronchial epithelial cells, other interferons such as the
more recently identified IFNλs, may dominate [10,11].
Thus, measuring type I IFNs alone does not necessarily
accurately assess cellular antiviral responses, and an
assay that measures antiviral responses due to multiple
types of interferons is required.
The biological effects of interferons are often measured
using reporter gene assays (RGAs), which use transgenic
cell lines expressing a reporter gene driven by an IFN-
responsive promoter [12-17]. These assays accurately
measure the presence or upregulation of single molecules,
such as Mx or various interferon-stimulated genes, and
provide valuable information on specific components of
an antiviral response. However, other assay methods are
necessary for the quantification of the integrated antiviral
effects of multiple-type interferon signaling, which is es-
sential for studying inhibition of virus spread [18,19].
Moreover, functional measures of secreted antiviraltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Voigt et al. Virology Journal 2013, 10:224 Page 2 of 10
http://www.virologyj.com/content/10/1/224signaling will be useful for advancing experimental and
computational models of virus-cell interactions and viral
infection spread in monolayers and tissues [20-24]. Such an
assay potentially has additional applications in the area of
high-throughput screening for antiviral compounds.
The most traditional form of a functional antiviral assay
is the assay based on cytopathic effect (CPE), commonly
used to determine the potency of purified interferon stocks.
In the CPE assay, antiviral activity is measured based on its
ability to inhibit virus-induced cytopathology as measured
by a crystal violet live-cell stain [25]. While widely used,
these types of assays are labor-intensive and contain many
handling steps that can disturb cell layers and increase vari-
ability. Additionally, successful infection that does not cause
major cytopathology is not detected by these assays. These
shortcomings can be addressed through the development
of reporter virus strains as robust readouts of virus replica-
tion. Examples include a luciferase-expressing reporter
strain of the BSL3 Rift Valley Fever virus and a non-
proliferative vesicular stomatitis virus (VSV) replicon also
expressing luciferase [2,26]. Here we create a replication-
competent fluorescent reporter VSV strain. We use this
virus in a simple, sensitive, and reproducible assay for de-
tection of secreted antiviral signaling activity. The assay
does not require the addition of expensive substrates elimi-
nates cell fixing, rinsing, and staining steps, and signifi-
cantly improves sensitivity, and reproducibility over the
traditional crystal violet CPE assay. Additionally, the broad
tropism of VSV allows for potential future assay adaptation
to a large range of host cell types [2,26].
Results
Synthesis of reporter virus constructs
We sought to create an assay to quantify overall activity of
secreted antiviral molecules with optimal sensitivity and re-
producibility. We therefore compared four detection
methods to determine antiviral activity: the traditional
crystal violet live-cell stain, Sytox® orange, a fluorescent
dead cell stain, and both a DsRed2-expressing and a
ZsGreen-expressing VSV reporter strain. Using fluorescent
reporters of VSV replication may increase assay sensitivity,
as inhibition of virus replication is a more direct measureFigure 1 Genotype maps of wild-type and fluorescent reporter VSV s
reverse-genetics, incorporating fluorescent reporter variants of GFP(ZsGreen
nucleocapsid protein (N), phosphoprotein (P), matrix protein (M), glycoprotof antiviral activity than cytopathology alone. We created
strains of DsRed2- or ZsGreen-encoding VSV with gen-
omic organization as indicated in Figure 1 for use in our
antiviral assays. We tested the ability of these recombinant
virus strains to infect A549 lung epithelial cells, and found
their replication rates comparable to that of their non-
fluorescent equivalent (Additional file 1: Figure S1) and a
multiplicity of infection (MOI) of 5 pfu/cell sufficient to
homogenously infect A549 monolayers (data not shown).
Comparison of assay readout methods
We compared the traditional virus-induced cytopathology
measurement (crystal violet after 28-hour infection) with a
more recently developed fluorescent dead cell stain
(Sytox®) and our two fluorescent VSV reporter strains. To
do so, we incubated A549 cells under 2-fold dilutions of
an IFNβ standard solution in media for 24 hours. The cells
were then infected with either wild-type or one of the
fluorescent reporter VSV strains as indicated in Figure 2,
at an MOI of 5 pfu/cell, and the infection was allowed to
progress for 28 hours. WtVSV-infected plates were rinsed
and stained as indicated. Assay results were quantified by
fluorescent scanning at the appropriate wavelengths and
subsequent normalization to positive (no IFN) and nega-
tive (no virus) controls, as shown in Figure 2.
We found that the fluorescent signal from DsRed2 and
ZsGreen reporter viruses created reproducible gradients
indicating decreasing viral replication due to increasing
IFN concentrations. These gradients were comparable to
those found by staining cells with crystal violet after
wtVSV replication and cell death. Sytox® fluorescent dead
cell stain also produced quantifiable gradients, but with a
significantly poorer antiviral detection limit (IC50 = 7.87
U/ml vs. <4 U/ml) than both crystal violet and fluorescent
virus assays.
Sensitivity and reproducibility comparison of fluorescent
reporter viruses
As fluorescent signals are generally more sensitive than
readouts of absorbance, and dead-cell stains require fixing
and staining steps that can disturb cell layers and increase
variability, we tested the reproducibility and sensitivitytrains used in this study. Recombinant VSV strains were created by
) and RFP(DsRed2) along with the five native VSV proteins:
ein (G), and large protein (L).
Figure 2 Comparison of live/dead cell stains and fluorescent-protein expressing assay virus. A549 cells were incubated under serial 2-fold
dilutions of recombinant human IFNβ for 24 hours, then infected with either wild-type or recombinant VSV as indicated at a multiplicity of 5 pfu/cell.
After 24 hours of infection, assay plates were stained, imaged, and quantified as discussed in the Methods section. Positive signal indicates cell survival
for the crystal violet assay, virus replication for the fluorescent virus assays, and cell death in the Sytox assay. Positive control wells are cells untreated by
antivirals and infected. Negative control wells are untreated, uninfected cells.
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compared it to that of the traditional crystal violet
cytopathology-based assay. Fluorescence was read both on
a standard fluorescent plate reader and also scanned with
a high-resolution GE Typhoon FLA 9000 Biomolecular
Imager, to determine which reading method is more sensi-
tive and reproducible. Sensitivity was defined as the limit
of detection (LOD), the lowest antiviral starting dose that,
upon two-fold serial dilution, would produce a dose–
response curve crossing the 50% viral inhibition point and
allow for accurate IC50 determination, as shown in Table 1.
Calculation of IC50 values for both quantification types
was done using linear interpolation within the linear dose-
dependent range of the indicated interferon treatment as
described in Methods. A sigmoidal-fit IC50 calculation
method was also tested, but showed no advantage over
linear interpolation.Both fluorescent reporter viruses significantly de-
creased the limit of detection and improved intra- and
inter-assay reproducibility over the traditional crystal
violet staining method. Sensitivity differences between
DsRed2 and ZsGreen were insignificant (p > 0.1). The
DsRed reporter virus showed better inter-assay repro-
ducibility than the ZsGreen virus when quantified by
fluorescent scanning. This may be due to fluorescent
background in the green absorption/emission spectrum
produced by the plastic microtiter plate (Figure 3).
There was no significant difference between the reporter
viruses for the plate reader quantification (p-value = 0.44).
Optimization of fluorescent signal
We determined the optimal time for signal development
by measuring a time course over 28 hours of signal de-
velopment as shown in Figure 3. As time progresses, the
Table 1 Assay statistics and reproducibility
A. Fluorescent plate scanner and whole-well signal integration
Sensitivity (LOD) units/ml
Variability intra-assay COV (%)
Variability inter-assay COV (%)
Assay1 Assay 2 Assay 3 Assay 4
IFNα
VSV-DsRed2 1.51 +/− 0.12 0.9 2.9 0.7 1.7 2.4
VSV-ZsGreen 2.07 +/− 0.94 1.8 8.6 5.5 3.3 16.0
IFNβ
VSV-DsRed2 1.71 +/− 0.27 1.4 1.1 0.6 1.0 5.1
VSV-ZsGreen 2.57 +/− 0.52 1.9 4.1 2.2 3.2 7.9
B. Fluorescence/absorbance plate reader
Sensitivity (LOD) units/ml
Variability intra-assay COV (%)
Variability inter-assay COV (%)
Assay 1 Assay 2 Assay 3 Assay 4
VSV-DsRed2 1.29 +/− 0.34 4.0 1.7 1.9 5.7 5.7
IFNα VSV-ZsGreen 0.96 +/−0.18 1.2 1.1 1.7 2.5 3.6
Crystal violet 4.09 +/− 0.43 17.5 14.0 7.3 8.6 21.9
VSV-DsRed2 2.71 +/− 0.29 3.0 1.8 1.7 3.6 6.4
IFNβ VSV-ZsGreen 1.87 +/− 0.11 2.3 3.1 0.7 1.8 4.4
Crystal violet 8.44 +/− 2.28 20.1 6.6 4.3 7.3 18.5
Viral replication reporters and two methods of signal measurement were tested for the functional antiviral assays and calculated IC50 values statistically compared
with the traditional crystal violet antiviral assay. Coefficients of variance were calculated with a minimum of four replicates. +/− values are 95% confidence
intervals over all samples.
Figure 3 Assay time-course development. Recombinant VSV antiviral activity assays were imaged on a fluorescent biomolecular imager every
four hours post-infection to monitor fluorescent signal development indicating viral replication. Mean fluorescence values were extracted from
plate images, normalized to positive and negative controls and plotted. Darker markers indicate longer development times. IC50 values were
calculated as described, and the coefficient of variance was calculated between four replicates at each time point.
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fluorescent intensity was observed at low interferon con-
centrations where reporter virus replicates more pro-
ductively. We found that a gradient sufficient for IC50
calculation first develops for the DsRed2 virus 16 hours
post-infection. The coefficient of variance decreases
until 28 hours post-infection, but met our goal of 1% co-
efficient of variance as early as 24 hours post-infection.
This gradient shows a linear range between 0.5 and 16
units/ml. The minimum measurable IC50 for each set of
conditions was between 1–3 units/ml for IFNβ, compar-
able to other published assays [2,6,12,14-17]. The coeffi-
cient of variation for the ZsGreen IC50 improves until
20 hours, then levels off but remains considerably higher
than for the VSV-DsRed2 assay. From these results, the
VSV-DsRed2 assay developed for 24–28 hours appears
optimal, providing excellent sensitivity, reproducibility
and lowest background. We chose a development time
of 24 hours as our standard for convenience. Our final
assay procedure and comparison to the traditional crys-
tal violet assay is shown in Table 2.
Validation of assay against human type I, II, and
III interferons
We tested the ability of the assay to detect antiviral activity
of several human type I, II, and III interferons, using the
final assay method as described in Table 2. Recombinant
human interferons α1 and β were used to represent type I
IFNs, IFNγ was tested as the sole type II IFN, and inter-
ferons λ1 (IL-29), λ2 (IL-28A) and λ3 (IL-28B) represented
type III IFNs. Antiviral activity was successfully detected
and measured from all IFN samples using our assay, as
shown in Figure 4. IC50 concentrations were lowest for
IFNβ, and highest for IFNγ, as expected. As the antiviral
effects of IFNγ are largely due to cell-mediated and adap-
tive immune responses absent in our assay, we measured
only the direct antiviral effects of IFNγ which are far less
potent than the type I and III interferons.
Demonstration of the assay to measure antivirals
produced in response to VSV infection
Finally, we tested the suitability of our assay for measur-
ing the kinetics of secretion of antiviral factors by an-
other human cell type infected with virus. We infectedTable 2 Comparison of infection reporter assay and the tradi
Crystal violet assay
Antiviral incubation 24 hours, 67ul sample
Infection wt virus, 24 hour incubation
Fixation 4% PFA in 5% sucrose, 20 min
Rinse 2x PBS
Stain Addition of crystal violet, overnight incubation
Scan Microplate reader at 570 nm Fparallel wells of prostate cancer (PC3) cells at MOI 50
with M51R-mutant VSV, a strain that is attenuated in its
ability to block the cellular antiviral response to infec-
tion [27]. Supernatants were sampled from parallel wells
over the course of infection. The titer of the supernatant
samples was measured by plaque assay. Separate aliquots
of supernatant were UV-irradiated to deactivate live
virus, serially diluted, and assayed (Figure 5).
Extracellular antiviral activity was first detected be-
tween 6 and 8 hours post-infection (hpi), rapidly rising
from 8 to 12 hpi, concurrent with the release of virus
progeny. The antiviral activity continued to increase at a
slower rate from 12 to 24 hpi before reaching a plateau.
The range of activity, which spanned four orders of mag-
nitude, represents the collective effects of all secreted
and extracellular factors that trigger antiviral responses
in A549 cells, independent of their specific pathways.
This highlights the ability of this method to capture an
integrated picture of the antiviral response.Discussion
We have developed a functional antiviral assay, based on
the inhibition of fluorescence produced during infection
by an engineered RFP reporter strain of vesicular stoma-
titis virus, which can be used to report the combined anti-
viral activity of human interferons α, β, γ, λ1, λ2, and λ3.
The assay shows an improvement in reproducibility over
most published assays, including more recently published
assays using luciferase reporter viruses or cells. Sensitivity
of the assay, as defined as the low limit of detection, is also
comparable to luciferase-based antiviral assays. However,
the linear range of luciferase assays has a higher saturation
concentration than the assay presented here, so further di-
lution of antiviral sample may sometimes be necessary
when using this method (see Additional file 2: Table S1 for
assay comparisons). The fluorescent reporter virus used in
this assay is also easily propagated on standard laboratory
cell lines, as opposed to non-replicative particles [28],
leading to cheaper, more renewable and readily available
assay reagents. Additionally, the assay avoids the use of lu-
ciferase reagents [2,12,14,28] which increase assay ex-
pense, and eliminates many handling steps which can
introduce variability and error.tional crystal violet antiviral assay
VSV-DsRed2 assay
24 hrs, 67ul sample
RFP reporter virus, 24 hour incubation
luorescent microplate reader 485/620 or fluorescent scanner 555/580 nm.
Figure 4 Validation of the assay’s ability to measure multiple interferon types. The final DsRed2 form of the assay was used to measure
antiviral activity of human type I (IFNα1, IFNβ), type II (IFNγ), and type III (IFNλ1, IFNλ2, IFNλ3) recombinant bioactive interferon standards.
IC50 values in pg/ml of added interferon were calculated as described, and are also shown in pmol/ml for molar comparisons.
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a good choice to assay for antiviral activities. However, if
the ability of antiviral signaling molecules to inhibit specific
viruses is of interest, or signaling in other tissue types is to
be more closely investigated, this assay could likely
be adapted for a multitude of virus/cell combinations.
Fluorescent-expressing viruses are common throughoutvirological research, allowing this method to be adapted
with a minimum of reagent development. Additionally, the
assay could potentially be usable for measuring antiviral
paracrine signals from samples obtained in vivo, such as ir-
radiated serum and nasal lavage. Due to its ease and low
expense, it could also be applied to the high-throughput
screening of small molecules for antiviral properties.
Figure 5 Kinetics of functional antiviral signaling and virus
progeny release of PC3 cells in response to virus infection. Data
points are averages of biological duplicates assayed in duplicate
(titer) or quadruplicate (activity). Three antiviral activity data points
(2, 4, and 6 hours post-infection) resulted in antiviral signal beneath
the assay detection limit (grey). Closed symbols: antiviral activity.
Open symbols: viral titer. Error bars are +/− standard deviation.
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is non-specific to a particular signaling pathway or net-
work, providing a measure that is complementary to
pathway-specific assays using bioengineered reporter
cells [12,14,16]. The assay can thus be used to detect
the collective effects of antiviral secreted factors from
various antiviral pathways. We note, however, that since
antiviral responses can be cell-type dependent, the use
of A549 cells makes this assay most suitable for studies
of antiviral secretions from respiratory cells. As such,
our assay is best suited for studies of early cellular re-
sponses to upper respiratory tract infections, such as
influenza A, respiratory syncytial virus, and some rhinovi-
ruses. Additionally, our assay is not limited to quantifying
the antiviral activity of interferons. Other secreted poten-
tially antiviral molecules include interferon-stimulated gene
15 (ISG15) [29-31], inflammatory factors such as TNFα
and IL-1β [32-34], and other species with antiviral function
such as various interleukins [35-37], interferon gamma-
induced protein 10 (IP-10), and antiviral microRNAs
[38-40]. While we have not specifically tested the ability of
our assay to detect these molecules, they may well contrib-
ute to the antiviral signal reported by our assay when test-
ing cellular or tissue responses to infection.
Extrapolation and application of any quantitative, kinetic
results obtained in cultured transformed cells to an in vivo
system should only be done with discretion. However,
characterizing the paracrine antiviral responses of cultured
cells and the integrated effects of the multiple types of re-
leased interferons is important to better understand thecomplex interaction of antiviral signaling and virus spread
throughout more intricate tissue systems.
Conclusions
The assay presented here provides a functional measure-
ment of antiviral activity of recombinantly expressed or
cellullarly secreted human type I, III, and III interferons.
It quantifies the potentially synergistic combination of
antiviral activities due to multiple types of interferons in
a biological sample, and is therefore complementary to
pathway-specific measures of cell responses.
Methods
Cell culture
Human lung epithelial carcinoma (A549, ATCC CCL-185)
and human prostate cancer (PC3, ATCC CRL-1435) cells
were obtained from American Type Culture Collection
and grown in RPMI 1640 medium (Gibco®) supplemented
with 10% fetal bovine serum (FBS) (Atlanta Biologicals,
Lawrenceville, GA). Baby hamster kidney (BHK-21) cells
for plaque assays, originally obtained from Isabel Novella
(University of Toledo), were grown in minimal essential
medium (MEM, Corning) with 10% FBS and 2 mM
Glutamax I (Gibco®). All cell lines were cultured in a hu-
midified incubator at 37°C in 5% CO2. Cells lines were
tested for mycoplasma contamination on a monthly basis.
Cytokines and reagents
Universal type I interferon (human interferon alpha A/D,
IFNα) and recombinant human IFN beta 1a (IFNβ) were
purchased from PBL InterferonSource (Piscataway, NJ).
Interferon antiviral activity levels in units/ml were con-
firmed by comparison with NIH standard Human Inter-
feron Beta (NR-3080) as obtained from BEI Resources
using the traditional interferon activity assay (VSV/A549)
as described below. Sytox® Orange nucleic acid dead cell
stain was obtained as a 5 mM solution in DMSO from
Invitrogen and used at a final concentration of 0.25 μM.
Crystal violet was obtained from PML Microbiologicals.
Recombinant human interferons alpha 1a, gamma,
lambda 1, lambda 2, and lambda 3 were obtained from
Cell Signaling Technology (Danvers, MA).
All experimental research in this work was done under
the oversight of the University of Wisconsin Institutional
Biosafety Committee and Office of Biological Safety. No
human or animal subjects were used.Virus strains
Fluorescent VSV reporter virus strains incorporating
either ZsGreen or DsRed2 into the fifth genomic pos-
ition of VSV-Indiana were created using published re-
verse genetics techniques [41,42]. Adapted plasmids
pBS-N, pBS-P, pBS-L, and pVSVFL(+) [42], for the
Voigt et al. Virology Journal 2013, 10:224 Page 8 of 10
http://www.virologyj.com/content/10/1/224expression of VSV N, P, and L genes and antigenomic
VSV RNA under a T7 promoter were generously pro-
vided by Dr. Valery Grdzelishvili [43]. ZsGreen1-DR
and DsRed2 genes (Clontech, Mountain View, CA)
were PCR-amplified with the following primers and









These primers incorporated an overlap with plasmid
pVSVFL(+) digested with NheI (overlap underlined) for
In-Fusion Cloning (Clontech) as well as an additional
VSV transcription unit (italicized) [44]. Successful inser-
tion of the fluorescent protein genes into plasmid
pVSVFL(+) was confirmed via Sanger sequencing.
In addition to the fluorescent VSV reporter strains, a re-
combinant VSV strain with a well-studied mutation to the
M protein was created. This methionine to arginine substi-
tution at the 51st amino acid abolishes the ability of VSV
M protein to inhibit host cell gene expression [45,46]. The
M51R mutation was introduced to the M protein region of
the genome via multistep PCR site-directed mutagenesis





PCR reaction A used primers XbaI For and M51R Rev,
and PCR reaction B used primers M51R For and NheI
Rev. These PCR reactions both created fragments with the
desired mutation, and because primers M51R For and
M51R Rev are reverse compliments of each other, the
products from PCR reactions A and B overlap for 36 bases.
Products A and B were mixed and used as templates with
primers XbaI For and NheI Rev in a third PCR reaction to
produce a DNA fragment that spanned between two
unique restriction enzyme sites and contained the desired
M51R mutation. This fragment was then cloned into
pVSVFL(+) digested with XbaI and NheI.
The presence of the desired mutation was confirmed
in the plasmid and recovered infectious VSV via Sanger
sequencing.
Infectious VSV was recovered from plasmid with T7
expressing vaccinia virus (VVT7), also from Valery
Grdzelishvili, on BHK cells at 36°C as previouslydescribed [41,42,47]. Recovered VSV was separated
from VVT7 via filtration with a 0.22 μm Millex GV filter
unit (Millipore, Billerica, MA), amplified for 2 days on
BHK cells, and plaque purified. A master and subse-
quent working stock of recovered recombinant VSV
were created from a single plaque. Growth curves con-
firmed the recombinant VSV strains to have similar
growth rates as recombinant wtVSV (Additional file 1:
Figure S1).
Antiviral activity assay
67 μl/well of A549 cells were seeded into 96-well micro-
titer plates at a density of 2.5×105 cells/ml and cultured
for 24 h before antiviral treatment. Interferon was diluted
serially 1:2 in RPMI media supplemented with 2% FBS to
final concentrations of 512 U/ml to 0.5 U/ml using an
epMotion 5070 automated pipetting system. Culture media
was vacuum aspirated from 96-well plates with confluent
cell monolayers, 67 μl/well of antiviral dilution or control
media was added, and plates were again incubated under
culture conditions for 24 hours. After 24-hour incubation,
cells were challenged with virus (wtVSV, VSV-ZsGreen or
VSV-DsRed2, as indicated) in 30 μl RPMI media + 2% FBS
per well added to the antiviral dilution for a final multipli-
city of infection (MOI) of 5 pfu/cell.
In the standard antiviral assay with wtVSV infection, the
infection was allowed to progress until cytopathic effects
were readily apparent in unprotected control cells (16–28
hpi, as indicated). The cell medium was discarded, and
cells were fixed with a solution of 4% paraformaldehyde
(w/v) and 5% sucrose (w/v) in PBS for 20 minutes. The
cells were rinsed twice with PBS (Sigma) and stained with
crystal violet (0.1% w/v) in 20% ethanol overnight.
Alternatively, wtVSV-infected, unfixed assay plates
were treated with fluorescent dead cell stain (Sytox® Or-
ange, Invitrogen) 28 hours post-infection as an endpoint
fluorescent readout of cell pathology. Fluorescent virus
replication was measured without stain or fixation.
Imaging
Crystal violet staining was measured with a Synergy H4
hybrid multi-mode microplate reader (BioTek) reading ab-
sorbance at 570 nm, and scanned using a desktop scanner
to obtain reference images. Sytox® Orange, ZsGreen, and
DsRed2 were detected by the microplate reader in fluores-
cence mode (485/620, 485/528, and 485/620, respectively).
All fluorescent assay plates were also scanned with a GE
Typhoon FLA 9000 Biomolecular Imager (ZsGreen 489/
508 nm, DsRed2 555/580 nm, Sytox® Orange 555/580 nm)
under BSL 2 conditions.
Image quantification and analysis
Fluorescent scanning images were analyzed by using JEX, a
customized JAVA-based batch processing image analysis
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J (Rasband, 1997–2012) that can be found as shareware
at <http://sourceforge.net/projects/jextools>. The mean
fluorescent intensity of each well was extracted using JEX.
Data for all assays were scaled using the following formula:
Sample read–average of uninfected control reads
Average of untreated; infected controls–average of uninfected control reads
IC50 value calculations for each dilution series were
found by linear least-squares regression through the three
data points in the linear range of the dose–response
curves closest to half-maximum intensity. Subsequent
interpolation determined the standard interferon dilu-
tion corresponding to a 50% decrease in signal above
background with respect to the positive (infected, un-
treated) and negative (uninfected, untreated) control
wells. The limit of detection was defined as the mini-
mum interferon concentration that resulted in an IC50
curve that included the 50% viral inhibition point.
Statistical analysis
For assay development the antiviral activity of interferon
samples were tested in quadruplicate. The intra-assay co-
efficient of variance (COV) was calculated using the aver-
age of the quadruplicate IC50 values and their standard
deviation. Inter-assay COV was calculated using average
data from four separate assays and the standard deviation
thereof. Comparisons between data sets were conducted
using a two-tailed Student’s t-test assuming unequal sam-
ple variances.
One-step virus infection
2 ml/well of PC3 cells were seeded in 6-well plates at a
density of 2.5 105 cells/ml and cultured for 24 h in RPMI
supplemented with 10% FBS, until cells formed 70-90%
confluent monolayers. Cells were then infected with mu-
tant VSV (M51R) at a multiplicity of 5 in 200 μl RPMI
with 2% FBS, and cells were incubated at 37°C for 1 h to
allow for adsorption with rocking at 20 minute intervals.
Mock-infected controls were incubated under 200 μl of
RPMI media with 2% FBS. All cells were then rinsed with
PBS once to remove unbound virus and 2 ml of RPMI
with 2% FBS was added. Infection was allowed to progress
under standard culture conditions. At the indicated times
post-infection measured from the initial point of virus
addition, supernatants were removed from cells and stored
at −80°C. The experiment was conducted with full bio-
logical duplicates for every sample.
Virus in 400 μl of each infection supernatant sample
was inactivated by exposure to 7000 J/m2 UVC irradi-
ation in standard 24-well tissue culture plates with
rocking over 20 minutes. Infection supernatants and cor-
responding controls were serially diluted in RPMI media
with 2% FBS and antiviral activity was quantified, withtechnical duplicates, using the antiviral activity assay
with the DsRed2-VSV reporter of viral replication. Virus
titers from each sample were quantified prior to irradi-
ation using standard plaque assays on BHK monolayers.Additional files
Additional file 1: Figure S1. Kinetics of VSV strain growth on A549
cells. A549 cells were infected in parallel wells, MOI = 10, and parallel
supernatant samples were taken over time and titered by
plaque assay.
Additional file 2: Table S1. A brief comparison of several published
antiviral assays.
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